Insulet (PODD) Competitors $266.58 +4.59 (+1.75%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PODD vs. ABMD, PEN, BDX, EW, RMD, IDXX, DXCM, STE, HOLX, and BAXShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Abiomed (ABMD), Penumbra (PEN), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Hologic (HOLX), and Baxter International (BAX). These companies are all part of the "medical" sector. Insulet vs. Abiomed Penumbra Becton, Dickinson and Company Edwards Lifesciences ResMed IDEXX Laboratories DexCom STERIS Hologic Baxter International Insulet (NASDAQ:PODD) and Abiomed (NASDAQ:ABMD) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings. Do analysts prefer PODD or ABMD? Insulet presently has a consensus price target of $253.27, suggesting a potential downside of 4.99%. Given Insulet's stronger consensus rating and higher probable upside, research analysts clearly believe Insulet is more favorable than Abiomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insulet 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.80Abiomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, PODD or ABMD? Insulet has higher revenue and earnings than Abiomed. Insulet is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsulet$1.98B9.43$206.30M$5.8445.65Abiomed$1.03B16.65$136.51M$5.8265.47 Is PODD or ABMD more profitable? Abiomed has a net margin of 24.84% compared to Insulet's net margin of 21.22%. Insulet's return on equity of 27.98% beat Abiomed's return on equity.Company Net Margins Return on Equity Return on Assets Insulet21.22% 27.98% 9.16% Abiomed 24.84%14.77%13.32% Which has more volatility and risk, PODD or ABMD? Insulet has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Does the MarketBeat Community believe in PODD or ABMD? Insulet received 188 more outperform votes than Abiomed when rated by MarketBeat users. Likewise, 66.15% of users gave Insulet an outperform vote while only 60.45% of users gave Abiomed an outperform vote. CompanyUnderperformOutperformInsuletOutperform Votes72366.15% Underperform Votes37033.85% AbiomedOutperform Votes53560.45% Underperform Votes35039.55% Do institutionals and insiders believe in PODD or ABMD? 94.5% of Abiomed shares are owned by institutional investors. 0.5% of Insulet shares are owned by company insiders. Comparatively, 2.5% of Abiomed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor PODD or ABMD? In the previous week, Insulet had 13 more articles in the media than Abiomed. MarketBeat recorded 13 mentions for Insulet and 0 mentions for Abiomed. Insulet's average media sentiment score of 0.99 beat Abiomed's score of 0.44 indicating that Insulet is being referred to more favorably in the media. Company Overall Sentiment Insulet Positive Abiomed Neutral SummaryInsulet beats Abiomed on 11 of the 18 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.70B$4.41B$5.03B$8.81BDividend YieldN/A41.16%5.16%4.06%P/E Ratio45.6524.82135.4117.82Price / Sales9.4347.021,160.9774.56Price / Cash68.5451.8733.5332.53Price / Book25.414.974.674.68Net Income$206.30M$13.76M$119.07M$226.08M7 Day Performance2.08%-1.08%-1.83%-1.04%1 Month Performance12.73%0.58%-3.60%1.04%1 Year Performance47.02%50.91%31.66%26.28% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.3848 of 5 stars$266.58+1.8%$253.27-5.0%+47.1%$18.38B$1.70B45.653,000ABMDAbiomedN/A$381.02flatN/A+0.0%$17.18B$1.03B65.472,003Analyst ForecastPENPenumbra4.3167 of 5 stars$239.20+0.9%$227.92-4.7%+1.6%$9.10B$1.06B278.144,200Analyst ForecastInsider TradeBDXBecton, Dickinson and Company4.9899 of 5 stars$222.41-0.1%$283.00+27.2%-4.8%$64.35B$20.18B37.4473,000Positive NewsEWEdwards Lifesciences4.1259 of 5 stars$69.54-0.9%$75.67+8.8%+3.5%$41.01B$6.00B10.0319,800Short Interest ↓Analyst RevisionRMDResMed4.797 of 5 stars$241.55+1.4%$225.70-6.6%+59.7%$34.96B$4.69B31.999,980Positive NewsIDXXIDEXX Laboratories4.8654 of 5 stars$418.61+0.5%$552.38+32.0%-11.5%$34.09B$3.66B40.3711,000Positive NewsDXCMDexCom4.9834 of 5 stars$75.24+0.5%$104.59+39.0%-30.9%$29.25B$3.95B45.059,600STESTERIS4.9928 of 5 stars$212.25+0.1%$253.00+19.2%+6.2%$20.93B$5.14B48.4618,179Analyst ForecastPositive NewsHOLXHologic4.8594 of 5 stars$78.04-0.7%$89.91+15.2%+8.5%$18.13B$4.03B23.446,990BAXBaxter International4.8157 of 5 stars$32.63+0.3%$40.91+25.4%-8.4%$16.60B$15.06B163.1560,000 Related Companies and Tools Related Companies Abiomed Alternatives Penumbra Alternatives Becton, Dickinson and Company Alternatives Edwards Lifesciences Alternatives ResMed Alternatives IDEXX Laboratories Alternatives DexCom Alternatives STERIS Alternatives Hologic Alternatives Baxter International Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PODD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
